Resources

Welcome to our searchable resource and literature collection on safer supply and related topics.

Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.

 

We provide a synopsis of the 2024 update of the 2018 National Guideline for the Clinical Management of Opioid Use Disorder, from the Canadian Research Initiative in Substance Matters (CRISM).

Guidelines | 2024
Clinical guidance, Harm reduction, Illegal drugs, Stigma, Substitution/OAT, Treatment/recovery, Withdrawal

The scope of the Publicly Available Specification (PAS) focuses on health-care providers who are able to prescribe medications in Canada with specific emphasis on prescribers who do not consider th

Guidelines | 2024
About prescribers, Alcohol, Barriers and enablers, Clinical guidance, Hospitals, Peer/PWLLE program involvement, Stigma, Substitution/OAT, Withdrawal
Guidelines | 2024
Clinical guidance, Hospitals, Substitution/OAT, Transitions in care/treatment

A human rights approach is essential to eliminating hepatitis C virus (HCV) as a public health threat, and capturing the social, cultural, economic, and other barriers to the enjoyment of rights, i

Guidelines | 2024
2SLGBTQI+, About PWUD, Advocacy, Barriers and enablers, Equity, Harm reduction, Indigenous, Injecting drugs, Policy/Regulatory, Sex/Gender , Stigma, Wrap-around services

To provide guidance on evidence-based strategies for the treatment of stimulant use disorders (StUDs), stimulant intoxication, and stimulant withdrawal, as well as se

Guidelines | 2024
About PWUD, Clinical guidance, Hospitals, Illegal drugs, Return to use, Stimulants, Substitution/OAT, Transitions in care/treatment, Withdrawal, Wrap-around services

This is a compilation of information and recommendations for the implementation and use of SROM in OAT. 

Guidelines | 2023
Substitution/OAT, Carries/take-home doses, Chronic pain, Clinical guidance, Transitions in care/treatment
Guidelines | 2023
Youth, Withdrawal, Hospitals, Clinical guidance, About prescribers
Guidelines | 2023
Stimulants, About prescribers, Clinical guidance
Guidelines | 2023
About prescribers, Withdrawal, Clinical guidance
Guidelines | 2023
Overdose, Clinical guidance
Guidelines | 2023
Clinical guidance, Harm reduction, Safer supply, About prescribers
Guidelines | 2023
Clinical guidance, Harm reduction, Safer supply, About prescribers

The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal takehome naloxone (THN) programs, using evidence from scientific and grey literature and co

Guidelines | 2023
Policy/Regulatory, Harm reduction, Clinical guidance, Overdose
Guide | 2023
à propos des pharmaciens, à propos des prescripteurs, les guides de pratique clinique, la politique / le cadre de réglementation, l'hésitation des prescripteurs, l'approvisionnement plus sécuritaire

Our objective was to provide preventive care recommendations that promote health equity by prioritizing effective interventions for people experiencing disadvantages.

Guidelines | 2023
Equity, Clinical guidance
Guide | 2023
les guides de pratique clinique, à propos des prescripteurs, à propos des pharmaciens, la surdose, la mortalité, la politique / le cadre de réglementation

We conducted a policy scan of UDS guidelines, examining the published clinical practice guidelines for each Canadian province and extracting all relevant data in March 2017.

Guidelines | 2018
Clinical guidance, Substitution/OAT, About prescribers

Refine Your Search

Keywords
Format
Region